SCHEMBL3940208

SCHEMBL3940208

CCO[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)C5CC5[C@@]4(C)[C@@H]3CC[C@@]21C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 7/20 0.48
▸ CYP3A4 P08684 6/20 0.48
▸ LMNA P02545 6/20 0.48
▸ PGR P06401 5/20 0.48
▸ MAPT P10636 4/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ ADORA3 P0DMS8 2/20 0.48
▸ SLC6A3 Q01959 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ NPSR1 Q6W5P4 2/20 0.48
▸ PDE3A Q14432 2/20 0.48
▸ HPGD P15428 1/20 0.48
▸ MLNR O43193 1/20 0.48
▸ NR1I2 O75469 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ PDE4D Q08499 1/20 0.48
▸ HIF1A Q16665 1/20 0.48
▸ AR P10275 4/20 0.48
▸ ALDH1A1 P00352 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10707185 0.91 NR3C1 (0.46) NR3C1CYP3A4LMNAPGRMAPT
SCHEMBL10703308 0.89 AR (0.54) NR3C1CYP3A4LMNAPGRMAPT
SCHEMBL10705465 0.89 CYP3A4 (0.60) NR3C1CYP3A4LMNAPGRMAPT
SCHEMBL11799696 0.89 CYP3A4 (0.60) NR3C1CYP3A4LMNAPGRMAPT
SCHEMBL10707423 0.88 NR3C1 (0.59) NR3C1CYP3A4LMNAPGRMAPT
SCHEMBL10704393 0.87 NR3C1 (0.66) NR3C1CYP3A4LMNAPGRMAPT
SCHEMBL3937302 0.86 NR3C2 (0.47) NR3C1CYP3A4LMNAPGRKMT2A
SCHEMBL10705476 0.85 NR3C1 (0.69) NR3C1CYP3A4LMNAPGRMAPT
SCHEMBL11799289 0.82 NR3C1 (0.61) NR3C1CYP3A4LMNAPGRMAPT
SCHEMBL4971448 0.78 LMNA (0.73) NR3C1CYP3A4LMNAPGRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1976997-B1 PROCESS FOR THE PREPARATION OF 11BETA-HYDR0XY-9BETA,10ALPHA-STEROIDS EMPLOYING AMYCOLATOPSIS MEDITERRANEI CELLS SOLVAY PHARM GMBH (DE) 2009-04-08 — — EP disclosed
US-20080249075-A1 C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds SOLVAY PHARMACEUTICALS GMBH (DE) 2008-10-09 — — US disclosed
EP-1976997-A1 PROCESS FOR THE PREPARATION OF 11BETA-HYDR0XY-9BETA, 10ALPHA -STEROIDS EMPLOYING AMYCOLATOPSIS MEDITERRANEI CELLS Solvay Pharmaceuticals GmbH (DE) 2008-10-08 — — EP disclosed
WO-2008113851-A2 NOVEL C11 MODIFIED RETROSTEROIDS AS PROGESTERONE RECEPTOR MODULATOR COMPOUNDS SOLVAY PHARMACEUTICALS GMBH (DE) 2008-09-25 — — WO disclosed
US-20070212751-A1 Microbial method for the 11beta hydroxylation of 9beta, 10alpha-steriods SOLVAY PHARMACEUTICALS GMBH (DE) 2007-09-13 — — US disclosed
WO-2007082891-A1 PROCESS FOR THE PREPARATION OF 11BETA-HYDR0XY-9BETA, 10ALPHA -STEROIDS EMPLOYING AMYCOLATOPSIS MEDITERRANEI CELLS SOLVAY PHARMACEUTICALS GMBH (DE) 2007-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249075-A1 C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds HSD17B11, CYP19A1, ESRRA NR3C1 49/4885CYP3A4 789/4885LMNA 1111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback